GENFIT
TOWARDS BETTER MEDICINE

PRESS RELEASE

GENFIT: 2019 Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Lille (France), Cambridge (Massachusetts, United States), January 10, 2020 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases, today announced the second half-year 2019 report of the liquidity contract with Crédit Industriel et Commercial.

Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of December 31, 2019:

- 18,132 shares
- €1,023,262.27

During the second half of 2019, total trading was:

- On the buy side: 1,344,696 shares for a total amount of €20,431,854.85
- On the sell side: 1,380,676 shares for a total amount of €21,070,894.13

During this same period in the second half of 2019, the number of trades were:

- On the buy side: 3,843
- On the sell side: 5,167

As a reminder, the following resources appeared on the liquidity account as of June 30, 2019:

- 27, 911 shares
- €769 849,43

ABOUT GENFIT

GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases where there are considerable unmet medical needs, corresponding to a lack of approved treatments. GENFIT is a leader in the field of nuclear receptor-based drug discovery, with a rich history and strong scientific heritage spanning almost two decades. Its most advanced drug candidate, elafibranor, is currently being evaluated in a pivotal Phase 3 clinical trial ("RESOLVE-IT") as a potential treatment for NASH, and GENFIT plans to initiate a Phase 3 clinical trial of elafibranor in

GENFIT
TOWARDS BETTER MEDICINE

PRESS RELEASE

PBC in 2020, following its positive Phase 2 results. As part of GENFIT's comprehensive approach to clinical management of patients with NASH, the company is also developing a new, non-invasive blood-based diagnostic test, NIS4, which, if approved, could enable easier identification of patients with NASH. With facilities in Lille and Paris, France, and Cambridge, MA, USA, the Company has approximately 200 employees. GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and in compartment B of Euronext's regulated market in Paris (Nasdaq and Euronext: GNFT). www.genfit.com

CONTACT

GENFIT | Investors

Naomi EICHENBAUM – Investor Relations | Tel: +1 (617) 714 5252 | investors@genfit.com

PRESS RELATIONS | Media

Hélène LAVIN – Press relations | Tel: +333 2016 4000 | helene.lavin@genfit.com

GENFIT
TOWARDS BETTER MEDICINE

PRESS RELEASE

APPENDIX
H2 2020

	Buy side			Sell side		
Date	**Number of executions**	**Number of shares**	**Traded amount in EUR**	**Number of executions**	**Number of shares**	**Traded amount in EUR**
TOTAL	**3 843**	**1 344 696**	**20 431 854,85**	**5 167**	**1 380 676**	**21 070 894,13**
01/07/2019	18	6 501	116 152,79	36	11 001	197 687,79
02/07/2019	28	11 351	201 767,80	28	5 501	98 857,80
03/07/2019	11	2 001	35 267,69	63	17 001	303 467,69
04/07/2019	22	13 355	236 058,24	52	15 588	277 229,49
05/07/2019	44	15 001	261 692,70	46	6 017	105 596,10
08/07/2019	49	18 001	306 672,41	26	4 461	76 508,41
09/07/2019	45	22 401	377 412,90	142	31 560	531 941,65
10/07/2019	17	11 065	189 281,99	121	27 265	465 894,01
11/07/2019	68	29 001	492 197,12	61	18 606	318 434,37
12/07/2019	60	19 988	335 628,86	105	27 080	455 897,36
15/07/2019	67	17 631	297 073,00	49	18 501	313 136,80
16/07/2019	9	2 378	40 418,36	55	13 300	226 024,75
17/07/2019	87	18 235	307 617,99	89	16 568	279 698,45
18/07/2019	42	25 629	436 999,55	73	23 001	396 046,80
19/07/2019	130	37 695	628 644,45	3	401	6 865,10
22/07/2019	27	11 072	180 779,85	126	30 700	504 183,80
23/07/2019	23	16 001	259 516,40	93	22 016	358 656,27
24/07/2019	11	5 001	80 186,17	78	18 001	290 721,17
25/07/2019	59	23 001	367 491,10	23	6 001	97 366,10
26/07/2019	19	18 284	290 972,68	82	24 618	393 018,85
29/07/2019	29	11 000	179 756,47	161	46 383	769 785,24
30/07/2019	30	14 950	239 533,00			
31/07/2019	18	3 500	55 240,00	18	6 500	103 309,77
01/08/2019	13	5 001	80 486,00	7	5 001	80 876,00
02/08/2019	4	1 200	18 940,00			
05/08/2019	29	16 001	238 925,60	52	13 120	194 230,37
06/08/2019	84	36 836	544 636,03	38	13 001	194 123,48
07/08/2019	65	30 001	441 524,73	43	21 744	322 057,03
08/08/2019	5	3 613	54 917,15	168	49 258	740 369,81
09/08/2019	183	56 001	832 676,01	17	4 613	69 520,72

GENFIT
TOWARDS BETTER MEDICINE

PRESS RELEASE

12/08/2019	91	20 701	300 812,40	52	12 581	186 357,23
13/08/2019	17	3 607	51 840,43	181	35 727	518 724,87
14/08/2019	88	27 525	395 407,84	71	14 698	212 350,65
15/08/2019	49	30 684	420 239,62	59	21 359	295 077,57
16/08/2019	20	8 001	110 733,66	217	59 506	847 313,66
19/08/2019	110	30 111	458 570,74	37	9 001	136 634,70
20/08/2019	43	21 189	315 370,20	17	2 001	30 415,20
21/08/2019	2	5 001	78 064,85	84	24 073	372 255,37
22/08/2019	23	9 001	139 165,50	43	10 001	156 165,50
23/08/2019	13	7 501	115 440,41	1	1	15,41
26/08/2019	16	7 001	106 415,20	66	17 037	264 019,27
27/08/2019	6	10 001	156 715,56	37	10 001	157 565,56
28/08/2019	28	7 349	115 802,75	62	17 315	278 396,30
29/08/2019	73	25 873	418 591,47	18	8 501	137 986,23
30/08/2019	34	10 001	160 036,20	1	1	16,20
02/09/2019	43	13 985	214 772,55	12	4 100	64 270,60
03/09/2019	48	11 301	168 540,17	45	19 024	283 970,17
04/09/2019	4	5 502	85 335,72	36	9 358	145 692,28
05/09/2019	5	264	4 189,54	48	14 599	231 819,96
06/09/2019	25	9 412	146 486,40	39	10 499	162 714,90
09/09/2019	34	13 001	200 025,45	20	2 979	46 074,45
10/09/2019	81	15 001	226 565,44	79	17 007	258 094,74
11/09/2019	4	1 662	26 209,14	48	10 996	169 849,07
12/09/2019	14	7 001	110 215,85	47	13 758	217 361,31
13/09/2019	20	5 001	78 615,70	6	3 001	47 665,70
16/09/2019	11	5 001	80 085,58	38	13 001	208 245,58
17/09/2019	82	23 155	369 668,31	3	266	4 256,25
18/09/2019	21	7 089	112 640,10	77	15 164	241 965,97
19/09/2019	15	5 001	81 116,00	67	13 852	224 712,30
20/09/2019	22	5 319	85 227,87	9	2 152	34 659,88
23/09/2019	39	9 183	145 344,40	1	1	16,04
24/09/2019	44	8 601	133 762,70	1	1	15,70
25/09/2019	36	7 990	120 783,96	1	1	15,50
26/09/2019	13	13 001	195 565,09	3	1 001	14 815,10
27/09/2019	10	2 001	29 314,80	42	7 522	111 792,07
30/09/2019	5	1 001	14 644,72	15	3 501	51 524,72
01/10/2019	22	5 501	78 159,81	32	9 501	141 734,81
02/10/2019	36	9 501	128 889,02	1	1	14,02

GENFIT
TOWARDS BETTER MEDICINE

PRESS RELEASE

03/10/2019	6	3 001	40 393,36	18	5 001	68 913,36
04/10/2019	11	3 221	43 124,66	38	13 500	182 230,00
07/10/2019	47	14 002	180 476,64	3	201	2 713,45
08/10/2019	19	9 501	116 756,45	43	14 501	181 077,70
09/10/2019	21	5 006	61 446,57	41	14 501	181 697,47
10/10/2019	21	6 001	74 807,90	12	3 127	39 220,76
11/10/2019	22	13 095	168 557,08	38	8 493	109 134,24
14/10/2019	2	2 001	26 813,08	29	12 458	167 828,01
15/10/2019	13	8 001	106 273,47	36	12 001	161 513,47
16/10/2019	28	7 001	93 513,44	25	9 001	121 213,44
17/10/2019	11	2 869	38 342,92	66	16 001	215 648,30
18/10/2019	68	14 501	192 853,50	3	499	6 661,80
21/10/2019	26	5 410	71 087,05	6	1 001	13 163,25
22/10/2019	28	9 578	125 446,06	11	2 501	32 953,13
23/10/2019	14	2 399	31 212,09	11	3 501	46 063,09
24/10/2019	6	1 501	19 978,28	15	3 501	46 923,28
25/10/2019	5	549	7 311,88	16	4 001	53 883,40
28/10/2019	1	1	13,50	72	24 070	331 879,50
29/10/2019	22	6 592	89 780,70	6	1 011	14 208,82
30/10/2019	17	7 036	93 979,00	1	1	13,50
31/10/2019	33	18 336	239 987,15	15	12 148	161 316,72
01/11/2019	21	8 959	114 469,85	1	1	12,87
04/11/2019	16	7 082	93 101,31	72	31 938	431 271,03
05/11/2019	28	15 541	207 766,85	11	6 344	86 565,06
06/11/2019	10	10 301	136 676,29	17	10 301	137 943,29
07/11/2019	3	2 001	26 613,30	4	2 001	26 733,30
08/11/2019	3	2 001	26 513,39	16	8 001	107 113,39
11/11/2019	23	14 251	208 615,45	41	22 589	325 342,23
12/11/2019	22	25 001	362 404,97	14	3 719	54 533,43
13/11/2019	3	3 001	42 514,53	10	3 001	42 664,53
14/11/2019	13	5 001	69 044,10	11	3 001	41 354,10
15/11/2019	3	2 001	27 113,80	10	2 001	27 257,84
18/11/2019	8	3 001	40 853,64	11	6 531	89 948,84
19/11/2019	5	1 529	21 173,74	9	3 546	49 066,54
20/11/2019	34	5 191	72 053,09	22	3 121	43 503,59
21/11/2019	46	14 783	204 329,80	28	5 172	71 599,35
22/11/2019	16	4 001	54 693,84	65	15 710	218 168,79
25/11/2019	54	14 001	194 214,02	65	21 720	307 021,67

GENFIT
TOWARDS BETTER MEDICINE

PRESS RELEASE

26/11/2019	27	8 001	112 513,92	74	17 282	245 066,27
27/11/2019	34	13 151	190 719,61	36	7 001	101 714,61
28/11/2019	31	5 851	82 979,31	16	3 001	42 714,31
29/11/2019	23	7 001	98 674,07	44	7 085	100 573,67
02/12/2019	27	11 001	155 784,38	33	7 917	114 834,78
03/12/2019	16	4 001	55 814,00	51	12 001	168 914,00
04/12/2019	19	4 457	63 285,05	39	6 001	85 664,25
05/12/2019	44	13 545	194 053,51	43	7 001	101 264,28
06/12/2019	30	5 001	71 294,29	23	5 001	71 814,29
09/12/2019	16	4 001	57 004,34	12	2 001	28 514,34
10/12/2019	36	8 001	114 294,11	53	10 001	143 514,15
11/12/2019	10	3 001	43 614,63	16	6 001	88 094,63
12/12/2019	18	6 001	87 754,37	69	12 357	183 894,17
13/12/2019	20	5 001	75 215,23	12	2 001	30 515,23
16/12/2019	36	7 001	107 715,22	36	9 001	139 245,22
17/12/2019	5	3 001	46 525,60	19	4 001	62 565,60
18/12/2019	27	7 171	110 559,92	8	2 001	31 215,52
19/12/2019	22	6 831	105 874,30	63	13 001	208 015,30
20/12/2019	25	8 001	131 016,50	15	4 380	72 670,00
23/12/2019	6	2 001	32 916,53	11	3 001	49 816,53
24/12/2019	13	3 001	50 966,74	33	7 001	118 916,74
27/12/2019	24	9 691	177 372,00	13	5 026	95 233,50
30/12/2019	46	10 311	186 314,01	37	5 001	90 868,51
31/12/2019	16	2 710	47 454,27	28	4 001	70 817,67